BioSpace News Archive

Phase 2 GRIFFIN data presented at ASH 2020 show increased stringent complete response and minimal residual disease negativity rates with maintenance therapy for transplant-eligible patients

Treatment options did not provide hematocrit control consistent with NCCN guidelines for up to 78 percent of patients as presented at the American Society for Hematology (ASH) 2020 annual meeting

Less than 1% of patients treated with CALQUENCE discontinued treatment due to cardiac adverse events in pooled analysis

Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) announce that preliminary data from firstMIND, the ongoing Phase 1b, open-label, randomized study on the safety and efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) were presented today during the 62nd American Society of Hematology Annual Meeting & Exposition

Beijing Biocytogen Co., Ltd., Biocytogen Boston Corp (collectively as “Biocytogen”) announced today that they have reached an agreement with Xencor, Inc., for the licensing of Biocytogen’s fully human antibody RenMab™/

DURECT Corporation (Nasdaq: DRRX) today announced that it has signed an agreement to sell its LACTEL Absorbable Polymer (LACTEL) product line to Evonik, a global leader in specialty chemicals. Under the terms of the agreement, Evonik will pay DURECT $15 million in exchange for certain assets and liabilities associated with

Medline and VitalTech announced an exclusive agreement to bring virtual care and remote patient monitoring solutions to the physician office market throughout the U.S. Telehealth adoption and usage by healthcare providers has grown significantly to offset a nearly 70% drop in in-person health care office visits.

Immunovia AB (publ) (“Immunovia”) a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced today that Julie Silber , Senior Director of Investor Relations has stepped down from her position to pursue other

Applied BioMath ( www.appliedbiomath.com ), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, is proud to welcome Dr. Theresa Yuraszeck as Director of Pharmacometrics and Clinical Pharmacology. In this role Theresa will be responsible

AUTO3 continues to show a differentiated product profile supporting outpatient administration Conference call and webcast to be held Monday , December 7 , 2020 at 4 :00 p m ET / 9 :00 pm GMT